Question 1

What does the CHA₂DS₂-VASc score predict?

Accepted Answer

CHA₂DS₂-VASc predicts annual ischemic stroke risk in patients with non-valvular atrial fibrillation and guides whether to initiate oral anticoagulation. The acronym stands for Congestive heart failure (1), Hypertension (1), Age ≥75 (2), Diabetes (1), Stroke/TIA/TE (2), Vascular disease (1), Age 65–74 (1), and Sex category female (1). Total range is 0–9.

Question 2

When should anticoagulation be started based on CHA₂DS₂-VASc?

Accepted Answer

Per the 2023 ACC/AHA/ACCP/HRS guideline: score 0 in men or 1 in women — no anticoagulation; score 1 in men or 2 in women — consider anticoagulation through shared decision-making; score ≥2 in men or ≥3 in women — anticoagulation is recommended (Class 1), with DOACs preferred over warfarin for non-valvular AF in patients without contraindications to DOACs. The 2024 ESC guideline applies the same thresholds to both sexes using the sex-neutral CHA₂DS₂-VA score (0 — none; 1 — consider; ≥2 — recommended).

Question 3

Why does female sex score 1 point in CHA₂DS₂-VASc?

Accepted Answer

Female sex is a stroke risk modifier in AF rather than a standalone risk factor: a woman with no other risk factors (score of 1 from sex alone) has very low absolute risk and does not require anticoagulation. The 2024 ESC AF guideline removed sex from the score altogether (CHA₂DS₂-VA), citing that it complicates clinical practice and excludes non-binary and transgender patients. The 2023 ACC/AHA guideline retains the sex point but raises the female anticoagulation threshold to ≥3 to reflect the same logic.

Question 4

What is the difference between CHA₂DS₂-VASc and CHADS₂?

Accepted Answer

CHA₂DS₂-VASc expands CHADS₂ by adding three risk factors: vascular disease (prior MI, peripheral artery disease, or aortic plaque), age 65–74, and female sex. The clinically important improvement is better identification of truly low-risk patients: a CHADS₂ of 0 still contains a substantial subset with annual stroke rates of 2–3% or higher when re-stratified by CHA₂DS₂-VASc, whereas CHA₂DS₂-VASc = 0 is consistently associated with annual stroke risk below 0.5%. Current ESC and ACC/AHA guidelines use CHA₂DS₂-VASc (or the 2024 ESC CHA₂DS₂-VA) rather than CHADS₂.

Question 5

How should CHA₂DS₂-VASc be used together with HAS-BLED?

Accepted Answer

The two scores are complementary, not competitive. CHA₂DS₂-VASc determines whether anticoagulation is needed; HAS-BLED estimates bleeding risk on anticoagulation. A high HAS-BLED is explicitly not a contraindication to anticoagulation in any current guideline — its role is to flag patients who need closer follow-up and to identify modifiable risks: uncontrolled hypertension, labile INR, concurrent NSAIDs or antiplatelet agents, and excessive alcohol intake. For most AF patients with a guideline indication for anticoagulation, the stroke-prevention benefit exceeds the bleeding risk even when HAS-BLED is elevated.

Question 6

What are the main limitations of CHA₂DS₂-VASc?

Accepted Answer

The score does not apply to valvular AF (moderate-to-severe mitral stenosis or any mechanical prosthetic valve), where warfarin is required regardless of score. It treats paroxysmal, persistent, and permanent AF the same and does not incorporate AF burden. Discrimination is moderate (c-statistic ~0.6 in most validation cohorts), so the score is best used as a binary decision aid rather than as a precise individual risk prediction. It also does not capture newer risk modifiers such as chronic kidney disease, obstructive sleep apnea, or thrombocytosis, which may further increase risk in selected patients.

Score	Annual stroke rate	Anticoagulation
0	0.2%	Not indicated
1	0.6%	Consider in men; not indicated in women
2	2.2%	Recommended in men; consider in women
3	3.2%	Recommended (DOAC preferred)
4	4.8%	Recommended
5	7.2%	Recommended
6	9.7%	Recommended
7	11.2%	Recommended
8	10.8%	Recommended
9	12.2%	Recommended

CHA₂DS₂-VASc Score

Criteria

About

Formula

Interpretation

References

FAQ

Related Calculators